Adaptive Biotechnologies Corporation
ADPT
Peringkat dalam Saham
#4165
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Harga Saham
$24.09
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$3.84B
Perubahan (1 hari)
-5.82%
Perubahan (1 tahun)
47.79%
Negara
US
Perdagangan Adaptive Biotechnologies Corporation (ADPT)
Kategori
Healthcare
Margin Operasi untuk Adaptive Biotechnologies Corporation (ADPT)
Margin Operasi per October 2026 TTM: -12.16%
Menurut laporan keuangan dan harga saham terbaru dari Adaptive Biotechnologies Corporation, margin operasi saat ini (TTM) adalah -12.16%. Pada akhir 2024, margin operasi perusahaan adalah -90.83%.
Riwayat margin operasi untuk Adaptive Biotechnologies Corporation dari 2017 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | -12.16% | -41.03% |
| 2025 | -20.62% | -77.30% |
| 2024 | -90.83% | -31.88% |
| 2023 | -133.33% | 23.42% |
| 2022 | -108.03% | -20.21% |
| 2021 | -135.39% | -12.84% |
| 2020 | -155.33% | 68.56% |
| 2019 | -92.15% | 3.09% |
| 2018 | -89.39% | -22.73% |
| 2017 | -115.68% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -103.17% |
US
|
|
| -149.01% | -87.75% |
US
|
|
| 25.57% | -102.10% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -102.37% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.